Clinical Trials

Upcoming Clinical Trials

A first-line dose-escalation study of SBP-101 in combination with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic cancer is expected to begin enrollment in Q2 of 2018.

Completed Clinical Trials

The First-Time-in-Human Phase 1 study of SBP-101 in patients with pancreatic ductal adenocarcinoma has reached completion in Australia and the United States. 

Click here for more information regarding the First-Time-in-Human Phase 1 study of SBP-101 in Australia.

Click here for more information regarding the Phase 1 study of SBP-101 in the United States.